play_arrow

keyboard_arrow_right

skip_previous play_arrow skip_next
00:00 00:00
playlist_play chevron_left
chevron_left
  • play_arrow

    YO1 York Yo1 Radio York

  • cover play_arrow

    The YO1 Breakfast Crew chat to Miss York 2021 YO1 Radio

  • play_arrow

    Liz is talking to the ladies from Lollipop admin

  • play_arrow

    Liz is talking to the ladies from Lollipop admin

National News

Study shows OxfordAstraZeneca jab less effective against South African mutation

todayFebruary 7, 2021 3

Background
share close

Study shows Oxford/AstraZeneca jab less effective against South African mutation

The Oxford/AstraZeneca vaccine offers only limited protection against mild disease caused by the South African variant of coronavirus, according to research.

But the British company said early data from the study, due to be published on Monday, has shown the jab can protect against severe disease caused by the mutation.

The study, first reported by the Financial Times, into the E484K mutation involved some 2,000 people, most of whom were young and healthy.

“We do believe our vaccine could protect against severe disease, as neutralising antibody activity is equivalent to that of other Covid-19 vaccines that have demonstrated activity against more severe disease, particularly when the dosing interval is optimised to eight to 12 weeks,” a spokesman reportedly said.

It comes after research released on Friday indicated that the Oxford/AstraZeneca jab is effective at fighting the new UK coronavirus variant.

Andrew Pollard, professor of paediatric infection and immunity, and chief investigator on the Oxford vaccine trial, said: “Data from our trials of the ChAdOx1 vaccine in the United Kingdom indicate that the vaccine not only protects against the original pandemic virus, but also protects against the novel variant, B117, which caused the surge in disease from the end of 2020 across the UK.”

Also on Friday, public health officials said the outcomes of targeted tests to track the South African variant in England could take up to two weeks.

Door-to-door testing as part of urgent efforts to swab 80,000 people came after 11 cases of the variant were identified in the previous few days in people who had no links to travel – suggesting it may be spreading in communities.

Published: by Radio NewsHub

Written by: YO1 Radio Web Team

Rate it

Previous post


0%